Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study

被引：0
|
作者：
Pandya, Amit G. [1 ,2 ]
Ezzedine, Khaled [3 ,4 ]
Passeron, Thierry [5 ,6 ]
van Geel, Nanja [7 ]
Brown, Kurt [8 ]
Santos, Leandro [8 ]
Erskine, Lois [8 ]
Wagya, Kofi [8 ]
Blauvelt, Andrew [9 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
[2] Palo Alto Fdn Med Grp, Sunnyvale, CA USA
[3] Henri Mondor Univ Hosp, Paris, France
[4] Univ Paris Est Creteil Val de Marne, Paris, France
[5] Univ Cote Azur, Ctr Hosp Univ Nice, Nice, France
[6] Univ Cote Azur, INSERM U1065, C3M, Nice, France
[7] Ghent Univ Hosp, Ghent, Belgium
[8] Incyte Corp, Wilmington, DE USA
[9] Oregon Med Res Ctr, Portland, OR USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
JAK1; inhibitor; oral administration; INCB054707; repigmentation; vitiligo;
D O I：
10.1093/bjd/ljae266.094
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
721
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)
    Marquardt, Tzvetelina
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Guttman-Yassky, Emma
    Bieber, Thomas
    Serra-Baldrich, Esther
    Simpson, Eric
    Rosmarin, David
    Elmaraghy, Hany
    Meskimen, Eric
    Natalie, Chitra R.
    Liu, Zhuqing
    Xu, Chenjia
    Pierce, Evangeline
    Morgan-Cox, MaryAnn
    Silverberg, Jonathan
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 62
  • [22] MERIDIAN: 52-week results from a phase 2, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of pegcetacoplan in people with amyotrophic lateral sclerosis
    Maragakis, Nicholas J.
    Estol, Conrado J.
    Jain, Gayatri
    Mandrioli, Jessica
    Petri, Susanne
    van den Berg, Leonard H.
    Kreisl, William Charles
    Zhang, Yiwei
    Kuzma-Kozakiewicz, Magdalena
    [J]. MUSCLE & NERVE, 2023, 68 : S67 - S68
  • [23] Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
    Mease, Philip J.
    Chohan, Saima
    Fructuoso, Ferran J. Garcia
    Luggen, Michael E.
    Rahman, Proton
    Raychaudhuri, Siba P.
    Chou, Richard C.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Gottlieb, Alice
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (09) : 1147 - 1157
  • [24] Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging placebo-controlled study
    Kirby, Joslyn S.
    Okun, Martin M.
    Alavi, Afsaneh
    Bechara, Falk G.
    Zouboulis, Christos C.
    Brown, Kurt
    Santos, Leandro L.
    Wang, Annie
    Bibeau, Kristen B.
    Kimball, Alexa B.
    Porter, Martina L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (03) : 521 - 529
  • [25] Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
    Blauvelt, Andrew
    Papp, Kim A.
    Merola, Joseph F.
    Gottlieb, Alice B.
    Cross, Nancy
    Madden, Cynthia
    Wang, Maggie
    Cioffi, Christopher
    Griffiths, Christopher E. M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1367 - 1374
  • [26] Phase 2 randomized, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of onabotulinumtoxina for the treatment of platysma prominence
    Rohrich, Rodney
    Bank, David E.
    Bertucci, Vince
    Biesman, Brian S.
    Dayan, Steven
    Humphrey, Shannon
    Jones, Derek
    Kaufman-Janette, Joely
    Muhn, Channy Y.
    Rivers, Jason K.
    Tong, Warren
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB171 - AB171
  • [27] The Design and Rationale of a Phase 2b, Randomized, Double-Blinded, and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B in Older Adults with Frailty
    K. Yousefi
    K. N. Ramdas
    J. G. Ruiz
    J. Walston
    H. Arai
    E. Volpi
    A. B. Newman
    C. Wang
    B. Hitchinson
    L. McClain-Moss
    L. Diaz
    G. A. Green
    J. M. Hare
    Anthony A. Oliva
    [J]. The Journal of Frailty & Aging, 2022, 11 : 214 - 223
  • [28] The Design and Rationale of a Phase 2b, Randomized, Double-Blinded, and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B in Older Adults with Frailty
    Yousefi, K.
    Ramdas, K. N.
    Ruiz, J. G.
    Walston, J.
    Arai, H.
    Volpi, E.
    Newman, A. B.
    Wang, C.
    Hitchinson, B.
    McClain-Moss, L.
    Diaz, L.
    Green, G. A.
    Hare, J. M.
    Oliva, Anthony A.
    [J]. JOURNAL OF FRAILTY & AGING, 2022, 11 (02): : 214 - 223
  • [29] Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo
    Passeron, Thierry
    Ezzedine, Khaled
    Hamzavi, Iltefat
    van Geel, Nanja
    Schlosser, Bethanee J.
    Hu, Xiaofei
    Huang, Xiaohong
    Rosmarin, David
    Harris, John E.
    Camp, Heidi S.
    Pandya, Amit G.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II64 - II65
  • [30] Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
    Stohl, William
    Merrill, Joan T.
    McKay, James D.
    Lisse, Jeffrey R.
    Zhong, Z. John
    Freimuth, William W.
    Genovese, Mark C.
    [J]. JOURNAL OF RHEUMATOLOGY, 2013, 40 (05) : 579 - 589
12345